pI: 7.115 |
Length (AA): 288 |
MW (Da): 30409 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
2 | 288 | 1nff (A) | 3 | 243 | 29.00 | 0 | 1 | 1.14 | -0.51 |
5 | 288 | 1e7w (A) | 5 | 288 | 99.99 | 0 | 1 | 2.16 | -1.46 |
2 | 78 | 1lu9 (A) | 116 | 191 | 22.00 | 0.79 | 0.49 | 0.587361 | -0.79 |
5 | 280 | 2xox (A) | 5 | 280 | 93.00 | 0 | 1 | 1.75013 | -0.43 |
5 | 288 | 1e7w (A) | 5 | 288 | 99.99 | 0 | 1 | 2.09191 | -0.77 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | amastigotes, metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_133937)
Species | Accession | Gene Product |
---|---|---|
Caenorhabditis elegans | CELE_R05D8.10 | Protein DHS-15 |
Escherichia coli | b2137 | putative oxidoreductase |
Escherichia coli | b1606 | dihydromonapterin reductase, NADPH-dependent |
Homo sapiens | 728635 | dehydrogenase/reductase (SDR family) member 4 like 1 |
Leishmania braziliensis | LbrM.23.0300 | pteridine reductase 1 |
Leishmania donovani | LdBPK_230310.1 | pteridine reductase 1 |
Leishmania infantum | LinJ.23.0310 | pteridine reductase 1 |
Leishmania major | LmjF.23.0270 | pteridine reductase 1 |
Leishmania mexicana | LmxM.23.0270 | pteridine reductase 1 |
Trypanosoma brucei | Tb927.8.2210 | pteridine reductase 1 |
Trypanosoma congolense | TcIL3000_8_2210 | pteridine reductase 1 |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.8.2210 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.2210 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.2210 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.8.2210 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
b1606 | Escherichia coli | non-essential | goodall |
b2137 | Escherichia coli | non-essential | goodall |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
growth (GO:0040007) | drug sensitive (PATO:0000529) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from loss-of-function mutant phenotype (ECO:0000016) | Leishmania major | 1763 48945 59943 547983 572016 572017 |
Annotator: | aaronjr@u.washington.edu. | Comment: | PTR1 null mutant leads to DHFR inhibitor sensitivity in promastigotes; successful inhibition of folate and pteridine metabolism will require complementary inhibition of DHFR and PTR1. | References: | 14981076 9153248 | |
growth (GO:0040007) | drug sensitive (PATO:0000529) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania major | 1763 48945 59943 547983 572016 572017 |
Annotator: | aaronjr@u.washington.edu. | Comment: | PTR1 null mutant leads to DHFR inhibitor sensitivity in promastigotes; successful inhibition of folate and pteridine metabolism will require complementary inhibition of DHFR and PTR1. | References: | 14981076 9153248 | |
growth (GO:0040007) | lethal (sensu genetics) (PATO:0000718) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from loss-of-function mutant phenotype (ECO:0000016) | Leishmania major | No drug identifiers listed for this gene. |
Annotator: | aaronjr@u.washington.edu. | Comment: | PTR1 null mutant leads to cell death in promastigotes, unless culture medium is supplemented with certain pteridines; . | References: | 9153248 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | promastigote (BTO:0001124) | inferred from bioassay (ECO:0000094) | Leishmania major | 1669 1763 1855 8083 16294 26764 48945 59943 242358 247198 354733 419420 547983 558652 558653 561919 565286 565287 571120 571121 572016 572017 572304 573463 |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 700-47-0; Drug: 704-61-0; Drug: 708-74-7; Drug: 945-24-4; Drug: 1026-36-4; Drug: 1597-01-9; Drug: 1899-40-7; Drug: 2432-24-8; Drug: 2440-80-4; Drug: 3977-17-1; Drug: 5774-32-3; Drug: 6954-23-0; Drug: 6973-01-9; Drug: 7319-50-8; Drug: 14684-54-9; Drug: 17005-34-4; Drug: 17005-35-5; Drug: 19152-86-4; Drug: 26398-12-9; Drug: 34244-78-5; Drug: 34244-80-9; Drug: 36804-91-8; Drug: 38713-63-2; Drug: 38713-64-3; Drug: 38713-65-4; Drug: 47066-05-7; Drug: 50691-65-1; Drug: 51395-54-1; Drug: 51583-00-7; Drug: 52128-15-1; Drug: 53219-56-0; Drug: 53274-34-3; Drug: 54798-36-6; Drug: 58091-86-4; Drug: 61267-65-0; Drug: 61267-67-2; Drug: 73978-42-4; Drug: 73978-43-5; Drug: 73978-44-6; Drug: 89977-50-4; Drug: 104422-58-4; Drug: 104422-59-5; Drug: 107174-41-4; Drug: 160602-03-9; Drug: 160602-12-0; Drug: 200127-49-7; Drug: 200127-50-0; Drug: 200127-51-1; Drug: 200127-52-2; Drug: 200127-53-3; Drug: 200127-54-4; Drug: 200127-55-5; Drug: 200127-57-7; Drug: 200127-58-8; Drug: 200127-59-9; Drug: 200127-60-2; Drug: 200127-61-3; Drug: 200127-62-4; Drug: 200127-63-5. chemical inhibition with DHFR and PTR1 inhibitors leads to slow growth of Leishmania sp. in cell assay; . | References: | 9371081 9398595 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania major | 1669 1763 1855 8083 16294 26764 48945 59943 242358 247198 354733 419420 547983 558652 558653 561919 565286 565287 571120 571121 572016 572017 572304 573463 | |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 700-47-0; Drug: 704-61-0; Drug: 708-74-7; Drug: 945-24-4; Drug: 1026-36-4; Drug: 1597-01-9; Drug: 1899-40-7; Drug: 2432-24-8; Drug: 2440-80-4; Drug: 3977-17-1; Drug: 5774-32-3; Drug: 6954-23-0; Drug: 6973-01-9; Drug: 7319-50-8; Drug: 14684-54-9; Drug: 17005-34-4; Drug: 17005-35-5; Drug: 19152-86-4; Drug: 26398-12-9; Drug: 34244-78-5; Drug: 34244-80-9; Drug: 36804-91-8; Drug: 38713-63-2; Drug: 38713-64-3; Drug: 38713-65-4; Drug: 47066-05-7; Drug: 50691-65-1; Drug: 51395-54-1; Drug: 51583-00-7; Drug: 52128-15-1; Drug: 53219-56-0; Drug: 53274-34-3; Drug: 54798-36-6; Drug: 58091-86-4; Drug: 61267-65-0; Drug: 61267-67-2; Drug: 73978-42-4; Drug: 73978-43-5; Drug: 73978-44-6; Drug: 89977-50-4; Drug: 104422-58-4; Drug: 104422-59-5; Drug: 107174-41-4; Drug: 160602-03-9; Drug: 160602-12-0; Drug: 200127-49-7; Drug: 200127-50-0; Drug: 200127-51-1; Drug: 200127-52-2; Drug: 200127-53-3; Drug: 200127-54-4; Drug: 200127-55-5; Drug: 200127-57-7; Drug: 200127-58-8; Drug: 200127-59-9; Drug: 200127-60-2; Drug: 200127-61-3; Drug: 200127-62-4; Drug: 200127-63-5. chemical inhibition with DHFR and PTR1 inhibitors leads to reduced enzyme activity in vitro; . | References: | 9371081 9398595 | |
growth (GO:0040007) | decreased time (PATO:0000716) | single cell organism (CARO:0000064) | amastigote (BTO:0000062) | inferred from bioassay (ECO:0000094) | Leishmania amazonensis | 1855 587877 |
Annotator: | aaronjr@u.washington.edu. | Comment: | chemical inhibition with DHFR-PTR1 inhibitors leads to slow growth of Leishmania sp. in cell assay; . | References: | 14502550 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania major | No drug identifiers listed for this gene. | |
Annotator: | aaronjr@u.washington.edu. | Comment: | Drug: 13741-90-7. chemical inhibition with PTR1 inhibitors leads to reduced enzyme activity in vitro; . | References: | 15388924 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.7
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Trypanosoma brucei | pteridine reductase 1 | Compounds | References |
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Cochliobolus lunatus | 17-beta-hydroxysteroid-dehydrogenase | 270 aa | 24.2% | 293 aa | Compounds | References |
Target | Type | Source | Notes |
---|---|---|---|
LmjF.23.0270 | cloned gene | BRENDA | A gene with this EC number or name or sequence has been cloned from Leishmania tarentolae ( 3 ) |
6 literature references were collected for this gene.